Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-27T12:00:30.337Z Has data issue: false hasContentIssue false
  • English
  • Français

Monitoring skills: diabetes

Published online by Cambridge University Press:  22 June 2006

L. Metcalfe
L. Metcalfe
Affiliation:
Diabetes Specialist Nurse, Wirral Hospital NHS Trust, Wirral, UK
Get access Rights & Permissions [Opens in a new window]

Extract

Summary

The extended independent and supplementary nurse prescribing programme implemented in 2003 is anticipated to have the potential to improve patient care by enabling faster access to medicine for people with chronic conditions such as Diabetes. Diabetes mellitus is a progressive, life–long, chronic condition which affects an estimated 1.4 million people in the UK and inevitably requires medication to control symptoms and prevent complications associated with the disease.

The supplementary prescribing option of nurse prescribing is an opportunity for Diabetes Specialist Nurses (DSN) to provide timely and appropriate clinical management for patients with diabetes within an agreed management plan. The clinical management plan (CMP) is a patient specific document and can only be implemented to enable supplementary nurse prescribing upon agreement by the individual patient, the independent prescriber (doctor or dentist and supplementary prescriber (nurse or pharmacist). The CMP allows the DSN to manage the treatment of the patient by modifying diabetes therapies tailored to the needs of the individual to achieve treatment goals. The use of a patient specific CMP compliments the National service Framework for diabetes requirement that all patients have a care plan. Involving the patient by seeking agreement to implement the CMP may improve concordance and compliance with therapies and treatment decisions.

Monitoring diabetes control is essential from diagnosis as the information received provides valuable feedback as to the effectiveness of therapies. Comprehensive diabetes education should be tailored to empower the patient with knowledge and skills to manage this chronic condition regardless of treatment regimes.

Consideration should always be given to the type of diabetes, the potential effects on lifestyle and treatment options available today.

Keywords

Nurse PrescribingDiabetes MellitusSupplementary PrescribingInsulin TherapyOral Hypoglycaemic AgentsClinical Management Plan
Type
Focus On
Information
Nurse Prescriber , Volume 1 , Issue 2 , February 2004 , pp. 1 - 6 , e17
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

DoH (2002a). Extending independent nurse prescribing within the NHS in England: A guide for implementation. London The Stationary Office
DoH (2002b). National Service Framework. A practical aid to implementation in primary care. London
NICE (2003a). Guidance on the use of patient – education models for diabetes. Technology Appraisal Guidance No. 60
DoH (2001a). National Service Framework for Diabetes: Standards. London: Department of Health
DoH (2001b) National Service Framework for Diabetes. London
Diabetes UK (2002). Diabetes and Pregnancy. London. Diabetes UK
UK Prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes: UKPDS 38. BMJ 317: 703–713
European guidelines on cardiovascular disease prevention in clinical practice (2003). European Heart Journal 24, 1601–1610
Thynne AD, Higgins B, Cummings MH. Choice of insulins, pen devices and blood glucose meters: factors influencing decision making by DSN's in the UK. Practical Diabetes International 2003; Vol. 20 No.7: 237–242Google Scholar
DoH (2001c). The Expert Patient. A New approach to disease management for the 21st century. London: Department of Health
NICE (2003b). Guidance on the use of patient – education models for diabetes. Technology Appraisal Guidance No. 60
BNF (2003). London: British Medical association and the Royal Pharmaceutical Society of Great Britain
NICE (2003c). Guidance on the use of glitazones for the treatment of type-2 diabetes. Technology Appraisal Guidance No. 63
Perry CG, Kernohan AFB, Petrie JR (2003). Hypertension in diabetes: what's new, what's true, what's next? Practical Diabetes International Vol. 20 No.7: 247–254
NICE (2002) Guidance on the management of Blood pressure and Lipids in type 2 diabetes: Clinical Guidance H